Zymedyne aims to develop safer, more effective treatments for chronic, neuropathic pain by targeting human Cav3.2 “T-type” calcium channels that are known to be crucial in pain signalling. Unlike opioids, our technology aims to achieve pain relief without the detrimental side effects of weight gain, respiratory depression and addiction that plague current users of opioid-based medications.
Chronic pain is a debilitating condition that affects up to 30% of adult Canadians and is one of the most serious health challenges that faces society today. Current therapies are not universally effective and often have detrimental adverse effects, such as weight gain (e.g., Gabapentinoids), respiratory depression (opioids) and addiction (opioid crisis). As a result, many patients are left with unmanaged chronic pain and new approaches are sorely needed. Zymedyne have the IP on a newly discovered molecular mechanism that causes T-Type calcium channel (protein)
In short, our mission is to develop next generation Non-opioid based Analgesics to improve Patient Quality of life.